Advanced search×

"Inverse benefit law" explains how drug marketing undermines patient safety.

Janice Hopkins Tanne

BMJ 342(7792):d598 (2011) PMID 21278216

DOI: 10.1136/bmj.d598
Version: za2963e q8zae q8zb1 q8zcc q8zd9 q8ze4 q8zf4 q8zg3
Buy PDF

Similar articles you may find interesting…

  1. Phase I/II RAF kinase inhibitors in cancer therapy.
    Samra Turajlic, Zohra Ali, and James Larkin

    Expert Opin Investig Drugs (2013) PMID 23642225

    Aberrant activation of RAF signalling is a frequent finding in human cancers. BRAF is the only RAF family member that is commonly mutated, whilst CRAF and ARAF play important roles in the signal transduction from mutant RAS. BRAF-specific inhibitors have been more effective in the treatment of BRAF-...
    Buy PDF
  2. Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells.
    Sui Huang

    Cancer Metastasis Rev (2013) PMID 23640024

    We review basic theoretical foundations and offer a dynamical systems perspective in which cancer is the inevitable pathological manifestation of modes of malfunction that are immanent to the complex gene regulatory network of the genome. We explain in an accessible, qualitative, and permissively si...
    Buy PDF
  3. Salvia divinorum: A Psychopharmacological Riddle and a Mind-Body Prospect.
    José-Luis Díaz

    Curr Drug Abuse Rev (2013) PMID 23627785

    The multidisciplinary research on Salvia divinorum and its chemical principles is analyzed concerning whether the ethnobotany, phytochemistry, mental effects, and neuropharmacology of this sacred psychoactive plant and main principle clarify its experienced effects and divinatory use...
    Buy PDF